Marc Lichtenfeld Blog | Talkmarkets | Page 1
Equities Analyst by Day/Ring Announcer by Night

Marc is the Chief Income Strategist for The Oxford Club and Wealthy Retirement, as well as Founder and Senior Editor of The Oxford Income Letter. He also contributes frequently to The Oxford Communiqué and Investment U.

Marc is Editor of VIP Trading ... more


Latest Posts
1 to 16 of 348 Posts
1 2 3 ... 22
SUN: Can This Double-Digit Yielder Keep Delivering?
Sunoco consistently raised the distribution every quarter until it hit $0.8255 per unit in November 2016, where it has remained since. It has never cut the distribution.
Will President Biden Sink The Stock Market?
President Biden has proposed trillions of dollars in stimulus spending and a hike in taxes on corporations and the wealthy. Anyone who is paying attention is expecting this to result in inflation.
Does Pfizer’s COVID-19 Vaccine Secure Its Dividend?
Even before the COVID-19 pandemic hit, Pfizer investors were likely drawn to the stock’s solid dividend and history of annual payout increases.
Why Phase 2 Trials Are Important To Investors (And Why I’m Enrolled In One)
The biotech sector tends to attract investors who are interested in exciting new medical advances and are drawn to big profits. There are lots of ways to invest in the sector.
The Secret To Successful Biotech Investing
As we advance in years, more people get sick and require more medicines for difficult-to-treat diseases. So if I could invest in only one sector for the next five or ten years, it would be biotech. But how do you choose which ones to invest in?
Downgrading Icahn’s 15% Yield
The company pays $2 per share quarterly. At the stock’s current price, that comes out to a 15% yield.
HH Have COVID-19 Vaccines Shifted The Pharma Pricing Debate?
Big Pharma and biotech are more or less recession-proof because a patient is generally not going to stop taking life-saving medicine just because the economy or the market is bad.
Why Gold Deserves A Place In Your Portfolio
Gold seems to make headlines every day now. If you don’t own any gold, should you buy some now? If you do already own some, should you buy more?
How To Be David To Wall Street’s Goliath
The longer you hold your Perpetual Dividend Raisers, the less performance you need out of the stocks – though companies that raise their dividends every year typically are growing earnings and cash flow and perform quite well.
NAT: A 12% Yield As Reliable As Your Crazy Friend
The Bermuda-based oil tanker company’s financial results are as consistent as a middle school orchestra. The main issue is that its free cash flow is all over the place.
COR: What Does Falling Cash Flow Mean For This Perpetual Dividend Raiser?
CoreSite has raised its dividend for 10 years in a row. It currently pays $1.23 per share quarterly, which comes out to an annual yield of 4.1%.
The Highest-Yielding Stocks With Insider Buying
There are lots of reasons company insiders sell their own companies’ stock. They may need to diversify or pay for a new mansion in the Hamptons, or they may know that earnings are going to be lousy in a few months.
DLR: Will This Previously “A” Rated Stock Be Forgiven?
After several years of annual increases in FFO, Digital Realty saw a slight decline in 2020.
This Company Is The Biggest Short In The Market
MicroStrategy (Nasdaq: MSTR) is all-in on Bitcoin. Last year, it said it planned to use Bitcoin as its primary treasury asset. That is simply irresponsible.
AT&T: A 7% Yield About To Be Upgraded
AT&T generates plenty of cash flow – more than enough to pay the dividend. Yet cash flow is declining. AT&T’s free cash flow slipped in 2020 and is expected to do so again in 2021.
Where There’s Smoke, There’s A 6% Yield
There are 1.3 billion smokers in the world, roughly 16% of the planet’s population. And surprisingly, Philip Morris International says it wants to change that.
1 to 16 of 348 Posts
1 2 3 ... 22